Scholarlink

Background <p>Bladder cancer (BC) represents a&#xa0;frequent invasive cancer. Individual behavior may effectively reduce the individual BC risk. Men are diagnosed with BC and die from BC three times more often than women.</p> Objectives <p>The work presents up-to-date results of the incidence of BC- and tumor-related mortality. It further demonstrates capacities of cancer registries to quantify morbidity and mortality resulting from neoplastic diseases in the population.</p> Materials and methods <p>Cancer registry data were used and included 5908 patients from Saarland newly diagnosed with invasive BC from 2004–2023. Observed rates of incidence and mortality as well as observed and cancer-specific survival up to 10&#xa0;years were reported for men and women.</p> Results <p>In 2022–2023, 44 and 15 invasive BC were diagnosed per 100,000 men and women, respectively. Two-thirds of the patients were aged ≥ 70&#xa0;years at diagnosis, 91% of the neoplasms were urothelial tumors, and 64% did not yet exceed the bladder (UICC stages&#xa0;I and&#xa0;II). Five years after diagnosis, 43% of the patients were still alive.</p> Conclusion <p>The results revealed significant tumor-related mortality across all groups of patients and particularly a&#xa0;higher tumor-specific mortality among women. It further highlighted the potential benefits of thus far unused opportunities for the primary prevention of BC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Zur Epidemiologie des invasiven Harnblasenkarzinoms – aktuelle Ergebnisse aus dem Krebsregister Saarland

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月20日

查看全文
  • Bernd Holleczek,
  • Christoph Lang,
  • Natalie Rath

摘要

Background

Bladder cancer (BC) represents a frequent invasive cancer. Individual behavior may effectively reduce the individual BC risk. Men are diagnosed with BC and die from BC three times more often than women.

Objectives

The work presents up-to-date results of the incidence of BC- and tumor-related mortality. It further demonstrates capacities of cancer registries to quantify morbidity and mortality resulting from neoplastic diseases in the population.

Materials and methods

Cancer registry data were used and included 5908 patients from Saarland newly diagnosed with invasive BC from 2004–2023. Observed rates of incidence and mortality as well as observed and cancer-specific survival up to 10 years were reported for men and women.

Results

In 2022–2023, 44 and 15 invasive BC were diagnosed per 100,000 men and women, respectively. Two-thirds of the patients were aged ≥ 70 years at diagnosis, 91% of the neoplasms were urothelial tumors, and 64% did not yet exceed the bladder (UICC stages I and II). Five years after diagnosis, 43% of the patients were still alive.

Conclusion

The results revealed significant tumor-related mortality across all groups of patients and particularly a higher tumor-specific mortality among women. It further highlighted the potential benefits of thus far unused opportunities for the primary prevention of BC.